QDEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
QuidelOrtho Corp (QDEL) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, options data suggests negative sentiment, and financial performance shows declining revenue and significant losses. While insider buying and the acquisition of LEX Diagnostics are positive catalysts, they are outweighed by the overall negative outlook.
The MACD is negatively expanding, RSI is neutral at 24.613, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 11.499, with resistance levels far above at 16.954 and 18.639. The stock trend analysis predicts further declines in the short to medium term.
Insiders are buying, with a 2578.44% increase in buying activity over the last month. The acquisition of LEX Diagnostics for $100 million is a strategic move to enhance molecular diagnostics and point-of-care testing capabilities.
Technical indicators and options data suggest bearish sentiment.
In Q3 2025, revenue dropped by -3.74% YoY to $699.9 million. Net income increased significantly to -$733 million (up 3583.42% YoY), but it remains a loss. EPS also improved to -10.78 (up 3493.33% YoY), but it is still negative. Gross margin slightly decreased to 41.13% (-0.44% YoY).
Analysts are generally neutral to bearish. UBS recently lowered its price target to $17 from $30, citing mixed 2026 guidance. Citi and JPMorgan have also adjusted targets, but ratings remain Neutral or Underweight.
